Table 4. Local Recurrence Difference in Molecular Subtypes.
HER2: human epidermal growth factor receptor-2; LA: luminal-A; LB: luminal-B; LR: local recurrence; SS: statistically significant; TN: triple negative; RR: recurrence rate
| Author (Ref. #) | Publish Year | Number of patients | Median Follow-up (Years) | Local Recurrence Rate % | P - value |
| Haffty [7] | 2006 | 482 | 7.9 | TN: 17; Non-TN: 17 | 0.823 |
| Dent [18] | 2007 | 1601 | 8.1 | TN: 13; Non-TN: 12 | 0.77 |
| Freedman [19] | 2009 | 753 | 5 | TN: 3.2; Luminal: 2.3; HER2: 4.6 | 0.36 |
| Ewan Millar [20] | 2009 | 498 | 7 | TN: 17.3; LA: 5.1; LB: 8.7; HER2: 15.4 | 0.012 |
| Gabos [21] | 2010 | 618 | 4.8 | HER2: HR 11.13; 95% CI 2.78 - 44.53; TN: HR 4.72; 95% CI 1.53 - 14.52 | SS |
| Kennecke [15] | 2010 | 2,985 | 12 | TN: 14; LA: 8; LB: 10; HER2: 21 | 0.005 |
| Noh [9] | 2011 | 596 | 6.6 | Luminal: 4.1%, TN: 7.0%, HER2: 10.1% | 0.151 |
| Lowery [22] | 2012 | 12,592 | 4.8 | Luminal: RR 0.34; 95% CI 0.26 - 0.45); TN: RR 0.38; 95% CI 0.23 - 0.61); HER2: RR 1.44; 95% CI 1.06 - 1.95) | SS |
| Muanza [16] | 2013 | 993 | 4.3 | LA: 1.8; LB: 7.4; HER2: 6.8; TN: 11.4 | 0.001 |